Vaccines · 2021 · 52 citations · 27 references
Veterinary MedicineImmunologyInfectious DiseasesMolecular VirologyVaccinologyVirologyRecombinant Protein VaccinesVaccinationVaccine Antigen DesignViral InfectionsViral VaccinesVirus-like Particle VaccinesCoronavirus VaccinesReceptor Binding Domain VaccinesRecombinant Virus-like ParticlesViral Receptor Binding DomainsViral Spike ProteinsViral-like Particle VaccinesVirus-like Particle Vaccine PlatformsVirus-like Particles
The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 million cases with deaths surpassing 2 million have been recorded worldwide, thus representing a major health and economic issues. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here, we demonstrated that the recombinantly expressed receptor-binding domain (RBD) of the spike protein can be coupled to immunologically optimized virus-like particles derived from cucumber mosaic virus (CuMVTT). The RBD displayed CuMVTT bound to ACE2, the viral receptor, demonstrating proper folding of RBD. Furthermore, a highly repetitive display of the RBD on CuMVTT resulted in a vaccine candidate that induced high levels of specific antibodies in mice, which were able to block binding of the spike protein to ACE2 and potently neutralize SARS-CoV-2 virus in vitro.
27
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al. · New England Journal of Medicine · 2020 · 31.2K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +10
Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text
Wanbo Tai, Lei He, Xiujuan Zhang et al. · Cellular and Molecular Immunology · 2020 · 1.8K citations · Full text